Annual CFF
$65.69 M
-$30.57 M-31.75%
December 31, 2023
Summary
- As of February 7, 2025, LYRA annual cash flow from financing activities is $65.69 million, with the most recent change of -$30.57 million (-31.75%) on December 31, 2023.
- During the last 3 years, LYRA annual CFF has fallen by -$22.01 million (-25.10%).
- LYRA annual CFF is now -31.75% below its all-time high of $96.26 million, reached on December 31, 2022.
Performance
LYRA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$23.00 K
+$66.00 K+74.16%
September 30, 2024
Summary
- As of February 7, 2025, LYRA quarterly cash flow from financing activities is -$23.00 thousand, with the most recent change of +$66.00 thousand (+74.16%) on September 30, 2024.
- Over the past year, LYRA quarterly CFF has increased by +$395.00 thousand (+94.50%).
- LYRA quarterly CFF is now -100.02% below its all-time high of $96.49 million, reached on June 30, 2022.
Performance
LYRA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$27.45 M
+$395.00 K+1.46%
September 30, 2024
Summary
- As of February 7, 2025, LYRA TTM cash flow from financing activities is $27.45 million, with the most recent change of +$395.00 thousand (+1.46%) on September 30, 2024.
- Over the past year, LYRA TTM CFF has dropped by -$19.32 million (-41.31%).
- LYRA TTM CFF is now -71.52% below its all-time high of $96.41 million, reached on June 30, 2022.
Performance
LYRA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
LYRA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -31.8% | +94.5% | -41.3% |
| 3 y3 years | -25.1% | +94.5% | -41.3% |
| 5 y5 years | +124.9% | +94.5% | -41.3% |
LYRA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -31.8% | >+9999.0% | -100.0% | +94.5% | -71.5% | >+9999.0% |
| 5 y | 5-year | -31.8% | >+9999.0% | -100.0% | +96.6% | -71.5% | >+9999.0% |
| alltime | all time | -31.8% | >+9999.0% | -100.0% | +96.6% | -71.5% | >+9999.0% |
Lyra Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$23.00 K(-74.2%) | $27.45 M(+1.5%) |
| Jun 2024 | - | -$89.00 K(-101.0%) | $27.06 M(-63.6%) |
| Mar 2024 | - | $8.64 M(-54.3%) | $74.33 M(+13.2%) |
| Dec 2023 | $65.69 M(-31.8%) | $18.92 M(-4626.3%) | $65.69 M(+40.5%) |
| Sep 2023 | - | -$418.00 K(-100.9%) | $46.77 M(-0.4%) |
| Jun 2023 | - | $47.19 M(>+9900.0%) | $46.95 M(-51.2%) |
| Mar 2023 | - | $4000.00(>+9900.0%) | $96.25 M(-0.0%) |
| Dec 2022 | $96.26 M(>+9900.0%) | $0.00(-100.0%) | $96.26 M(+0.0%) |
| Sep 2022 | - | -$236.00 K(-100.2%) | $96.25 M(-0.2%) |
| Jun 2022 | - | $96.49 M(>+9900.0%) | $96.41 M(>+9900.0%) |
| Mar 2022 | - | $6000.00(-250.0%) | $103.00 K(-71.3%) |
| Dec 2021 | $359.00 K | -$4000.00(-95.2%) | $359.00 K(-3.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$84.00 K(-145.4%) | $370.00 K(-267.4%) |
| Jun 2021 | - | $185.00 K(-29.4%) | -$221.00 K(-100.4%) |
| Mar 2021 | - | $262.00 K(+3642.9%) | $58.50 M(-33.3%) |
| Dec 2020 | $87.70 M(<-9900.0%) | $7000.00(-101.0%) | $87.70 M(+0.2%) |
| Sep 2020 | - | -$675.00 K(-101.1%) | $87.50 M(-0.8%) |
| Jun 2020 | - | $58.91 M(+99.9%) | $88.17 M(+200.4%) |
| Mar 2020 | - | $29.46 M(<-9900.0%) | $29.35 M(<-9900.0%) |
| Dec 2019 | -$115.00 K(-100.4%) | -$198.00 K(+4850.0%) | -$115.00 K(-238.6%) |
| Sep 2019 | - | -$4000.00(-104.6%) | $83.00 K(-4.6%) |
| Jun 2019 | - | $87.00 K(>+9900.0%) | $87.00 K(>+9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | $29.21 M | - | - |
FAQ
- What is Lyra Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Lyra Therapeutics?
- What is Lyra Therapeutics annual CFF year-on-year change?
- What is Lyra Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Lyra Therapeutics?
- What is Lyra Therapeutics quarterly CFF year-on-year change?
- What is Lyra Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Lyra Therapeutics?
- What is Lyra Therapeutics TTM CFF year-on-year change?
What is Lyra Therapeutics annual cash flow from financing activities?
The current annual CFF of LYRA is $65.69 M
What is the all time high annual CFF for Lyra Therapeutics?
Lyra Therapeutics all-time high annual cash flow from financing activities is $96.26 M
What is Lyra Therapeutics annual CFF year-on-year change?
Over the past year, LYRA annual cash flow from financing activities has changed by -$30.57 M (-31.75%)
What is Lyra Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of LYRA is -$23.00 K
What is the all time high quarterly CFF for Lyra Therapeutics?
Lyra Therapeutics all-time high quarterly cash flow from financing activities is $96.49 M
What is Lyra Therapeutics quarterly CFF year-on-year change?
Over the past year, LYRA quarterly cash flow from financing activities has changed by +$395.00 K (+94.50%)
What is Lyra Therapeutics TTM cash flow from financing activities?
The current TTM CFF of LYRA is $27.45 M
What is the all time high TTM CFF for Lyra Therapeutics?
Lyra Therapeutics all-time high TTM cash flow from financing activities is $96.41 M
What is Lyra Therapeutics TTM CFF year-on-year change?
Over the past year, LYRA TTM cash flow from financing activities has changed by -$19.32 M (-41.31%)